Symbols / MDLN Stock $36.61 -1.40% Medline Inc.
MDLN (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteMedline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-06-03 | main | Baird | Outperform → Outperform | $45 |
| 2026-06-01 | main | Barclays | Overweight → Overweight | $45 |
| 2026-05-14 | main | BNP Paribas | Neutral → Neutral | $40 |
| 2026-05-13 | main | Tigress Financial | Buy → Buy | $62 |
| 2026-05-07 | main | Citigroup | Buy → Buy | $55 |
| 2026-05-07 | main | Bernstein | Outperform → Outperform | $54 |
| 2026-05-07 | reit | BTIG | Buy → Buy | $55 |
| 2026-03-10 | main | JP Morgan | Overweight → Overweight | $53 |
| 2026-03-09 | main | Tigress Financial | Buy → Buy | $60 |
| 2026-03-09 | reit | BTIG | Buy → Buy | $55 |
| 2026-03-02 | main | Morgan Stanley | Overweight → Overweight | $52 |
| 2026-02-27 | main | Wells Fargo | Equal-Weight → Equal-Weight | $47 |
| 2026-02-26 | main | Citigroup | Buy → Buy | $60 |
| 2026-02-26 | main | UBS | Buy → Buy | $57 |
| 2026-02-26 | main | BMO Capital | Outperform → Outperform | $54 |
| 2026-02-26 | main | RBC Capital | Outperform → Outperform | $53 |
| 2026-02-26 | main | Evercore ISI Group | Outperform → Outperform | $55 |
| 2026-02-05 | init | Tigress Financial | — → Buy | $55 |
| 2026-01-12 | init | Citigroup | — → Buy | $48 |
| 2026-01-12 | init | Stifel | — → Buy | $46 |
- Medline (NASDAQ: MDLN) investors back directors, pay plan and EY auditor - Stock Titan Fri, 12 Jun 2026 20
- Is Medline (MDLN) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential? - Yahoo Finance ue, 09 Jun 2026 17
- Why Is Medline Stock Falling Friday? - Medline (NASDAQ:MDLN) - Benzinga Fri, 12 Jun 2026 18
- Insider Purchase: Principal Accounting Officer of $MDLN Buys 5,000 Shares - Quiver Quantitative ue, 09 Jun 2026 20
- Medline’s 2026: Will a PE-Backed IPO Transform Healthcare’s Future? - Phemex Fri, 12 Jun 2026 04
- Sharon AI surges premarket; New Oriental gains, Medline slips By Investing.com - Investing.com Nigeria Fri, 12 Jun 2026 19
- Is Medline (MDLN) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential? - Insider Monkey ue, 09 Jun 2026 17
- Fjarde AP Fonden Fourth Swedish National Pension Fund Takes $1.89 Million Position in Medline $MDLN - MarketBeat Wed, 10 Jun 2026 09
- How to Buy Medline Stock (MDLN) in 2026 - The Motley Fool Wed, 20 May 2026 07
- Assessing Medline (MDLN) Valuation After Recent Share Price Pullback - Yahoo Finance Mon, 25 May 2026 07
- Medline shares rise as investors digest recent refinancing and large secondary offering - Quiver Quantitative ue, 09 Jun 2026 21
- Blackstone-linked holders sell 72,554,594 Medline shares at $37 - Stock Titan hu, 28 May 2026 07
- Leerink maintains Medline stock rating after California fire - Investing.com Fri, 12 Jun 2026 13
- Insider Buying: Medline (NASDAQ:MDLN) Insider Acquires 5,000 Shares of Stock - MarketBeat ue, 09 Jun 2026 21
- Is Medline Inc. (MDLN) A Good Stock To Buy Now? - Yahoo Finance Mon, 06 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Total Revenue |
|
28,432.00
|
| Operating Revenue |
|
28,432.00
|
| Cost Of Revenue |
|
20,914.00
|
| Reconciled Cost Of Revenue |
|
20,607.00
|
| Gross Profit |
|
7,518.00
|
| Operating Expense |
|
5,306.00
|
| Selling General And Administration |
|
4,524.00
|
| Other Operating Expenses |
|
78.00
|
| Total Expenses |
|
26,220.00
|
| Operating Income |
|
2,212.00
|
| Total Operating Income As Reported |
|
2,212.00
|
| EBITDA |
|
3,071.00
|
| Normalized EBITDA |
|
3,159.00
|
| Reconciled Depreciation |
|
1,011.00
|
| EBIT |
|
2,060.00
|
| Total Unusual Items |
|
-88.00
|
| Total Unusual Items Excluding Goodwill |
|
-88.00
|
| Net Income |
|
1,159.00
|
| Pretax Income |
|
1,248.00
|
| Net Non Operating Interest Income Expense |
|
-812.00
|
| Interest Expense Non Operating |
|
812.00
|
| Net Interest Income |
|
-812.00
|
| Interest Expense |
|
812.00
|
| Other Income Expense |
|
-152.00
|
| Other Non Operating Income Expenses |
|
-64.00
|
| Gain On Sale Of Security |
|
-88.00
|
| Tax Provision |
|
91.00
|
| Tax Rate For Calcs |
|
0.00
|
| Tax Effect Of Unusual Items |
|
-6.42
|
| Net Income Including Noncontrolling Interests |
|
1,157.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
1,159.00
|
| Net Income From Continuing And Discontinued Operation |
|
1,159.00
|
| Net Income Continuous Operations |
|
1,157.00
|
| Minority Interests |
|
2.00
|
| Normalized Income |
|
1,240.58
|
| Net Income Common Stockholders |
|
1,159.00
|
| Diluted EPS |
|
-0.01
|
| Basic EPS |
|
-0.01
|
| Basic Average Shares |
|
810.00
|
| Diluted Average Shares |
|
810.00
|
| Diluted NI Availto Com Stockholders |
|
1,159.00
|
| Amortization |
|
704.00
|
| Amortization Of Intangibles Income Statement |
|
704.00
|
| Depreciation Amortization Depletion Income Statement |
|
704.00
|
| Depreciation And Amortization In Income Statement |
|
704.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets |
|
38,484.00
|
—
|
—
|
| Current Assets |
|
10,679.00
|
—
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
1,939.00
|
—
|
—
|
| Cash And Cash Equivalents |
|
1,939.00
|
—
|
—
|
| Receivables |
|
3,533.00
|
—
|
—
|
| Accounts Receivable |
|
3,533.00
|
—
|
—
|
| Gross Accounts Receivable |
|
3,685.00
|
—
|
—
|
| Allowance For Doubtful Accounts Receivable |
|
-152.00
|
—
|
—
|
| Inventory |
|
4,769.00
|
—
|
—
|
| Raw Materials |
|
748.00
|
—
|
—
|
| Finished Goods |
|
4,021.00
|
—
|
—
|
| Other Current Assets |
|
438.00
|
—
|
—
|
| Total Non Current Assets |
|
27,805.00
|
—
|
—
|
| Net PPE |
|
4,778.00
|
—
|
—
|
| Goodwill And Other Intangible Assets |
|
21,972.00
|
—
|
—
|
| Goodwill |
|
8,079.00
|
—
|
—
|
| Other Intangible Assets |
|
13,893.00
|
—
|
—
|
| Non Current Deferred Assets |
|
583.00
|
0.00
|
—
|
| Non Current Deferred Taxes Assets |
|
583.00
|
0.00
|
—
|
| Other Non Current Assets |
|
472.00
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
19,198.00
|
—
|
—
|
| Current Liabilities |
|
2,490.00
|
—
|
—
|
| Payables And Accrued Expenses |
|
1,539.00
|
—
|
—
|
| Payables |
|
1,072.00
|
—
|
—
|
| Accounts Payable |
|
961.00
|
—
|
—
|
| Current Accrued Expenses |
|
467.00
|
—
|
—
|
| Total Tax Payable |
|
111.00
|
—
|
—
|
| Income Tax Payable |
|
24.00
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
143.00
|
—
|
—
|
| Current Debt |
|
77.00
|
—
|
—
|
| Other Current Borrowings |
|
77.00
|
—
|
—
|
| Current Capital Lease Obligation |
|
66.00
|
—
|
—
|
| Other Current Liabilities |
|
808.00
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
16,708.00
|
—
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
12,484.00
|
—
|
—
|
| Long Term Debt |
|
12,484.00
|
—
|
—
|
| Other Non Current Liabilities |
|
4,224.00
|
—
|
—
|
| Stockholders Equity |
|
10,737.00
-35.02%
|
16,524.00
+29943.64%
|
55.00
|
| Common Stock Equity |
|
10,737.00
-35.02%
|
16,524.00
+29943.64%
|
55.00
|
| Capital Stock |
|
0.00
|
0.00
|
—
|
| Common Stock |
|
0.00
|
0.00
|
—
|
| Preferred Stock |
|
0.00
|
0.00
|
—
|
| Share Issued |
|
812.00
+0.00%
|
812.00
+1.53%
|
799.80
|
| Ordinary Shares Number |
|
812.00
+0.00%
|
812.00
+1.53%
|
799.80
|
| Additional Paid In Capital |
|
10,717.00
|
0.00
|
—
|
| Retained Earnings |
|
-7.00
|
0.00
|
—
|
| Gains Losses Not Affecting Retained Earnings |
|
27.00
-99.83%
|
16,158.00
|
—
|
| Minority Interest |
|
8,549.00
|
0.00
|
—
|
| Other Equity Adjustments |
|
27.00
-99.83%
|
16,158.00
|
—
|
| Total Equity Gross Minority Interest |
|
19,286.00
|
—
|
—
|
| Total Capitalization |
|
23,221.00
|
—
|
—
|
| Working Capital |
|
8,189.00
|
—
|
—
|
| Invested Capital |
|
23,298.00
-29.44%
|
33,018.00
+99.24%
|
16,572.00
|
| Total Debt |
|
12,627.00
|
—
|
—
|
| Net Debt |
|
10,622.00
|
—
|
—
|
| Capital Lease Obligations |
|
66.00
|
—
|
—
|
| Net Tangible Assets |
|
-11,235.00
-84.18%
|
-6,100.00
+72.60%
|
-22,265.00
|
| Tangible Book Value |
|
-11,235.00
-84.18%
|
-6,100.00
+72.60%
|
-22,265.00
|
| Interest Payable |
|
144.00
|
—
|
—
|
| Limited Partnership Capital |
|
—
|
16,384.00
-2.09%
|
16,734.00
|
| Other Equity Interest |
|
—
|
366.00
|
—
|
| Total Partnership Capital |
|
—
|
16,395.00
-3.11%
|
16,922.00
|
| Line Item | Trend | 2025-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Cash Flow |
|
1,744.00
|
—
|
| Cash Flow From Continuing Operating Activities |
|
1,744.00
|
—
|
| Net Income From Continuing Operations |
|
1,157.00
|
—
|
| Depreciation Amortization Depletion |
|
1,011.00
|
—
|
| Depreciation And Amortization |
|
1,011.00
|
—
|
| Other Non Cash Items |
|
144.00
-32.08%
|
212.00
|
| Stock Based Compensation |
|
76.00
|
—
|
| Provisionand Write Offof Assets |
|
54.00
|
—
|
| Operating Gains Losses |
|
85.00
+2733.33%
|
3.00
|
| Gain Loss On Investment Securities |
|
-41.00
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
68.00
|
—
|
| Change In Working Capital |
|
-783.00
-493.47%
|
199.00
|
| Change In Receivables |
|
-355.00
|
—
|
| Changes In Account Receivables |
|
-355.00
|
—
|
| Change In Inventory |
|
-264.00
|
—
|
| Change In Payables And Accrued Expense |
|
-19.00
|
—
|
| Change In Accrued Expense |
|
-92.00
|
—
|
| Change In Payable |
|
73.00
|
—
|
| Change In Account Payable |
|
73.00
|
—
|
| Change In Other Current Assets |
|
-126.00
|
—
|
| Change In Other Current Liabilities |
|
-19.00
+20.83%
|
-24.00
|
| Investing Cash Flow |
|
-474.00
|
—
|
| Cash Flow From Continuing Investing Activities |
|
-474.00
|
—
|
| Net PPE Purchase And Sale |
|
-447.00
|
—
|
| Purchase Of PPE |
|
-447.00
-62.55%
|
-275.00
|
| Capital Expenditure |
|
-447.00
-62.55%
|
-275.00
|
| Net Business Purchase And Sale |
|
6.00
|
—
|
| Net Other Investing Changes |
|
-33.00
-57.14%
|
-21.00
|
| Financing Cash Flow |
|
399.00
|
—
|
| Cash Flow From Continuing Financing Activities |
|
399.00
|
—
|
| Net Issuance Payments Of Debt |
|
-4,092.00
|
—
|
| Issuance Of Debt |
|
7,748.00
|
—
|
| Repayment Of Debt |
|
-11,840.00
|
—
|
| Long Term Debt Issuance |
|
7,748.00
|
—
|
| Long Term Debt Payments |
|
-11,840.00
|
—
|
| Net Long Term Debt Issuance |
|
-4,092.00
|
—
|
| Net Common Stock Issuance |
|
5,045.00
|
—
|
| Common Stock Payments |
|
-2,003.00
|
—
|
| Common Stock Dividend Paid |
|
-518.00
|
—
|
| Cash Dividends Paid |
|
-518.00
|
—
|
| Repurchase Of Capital Stock |
|
-2,003.00
|
—
|
| Net Other Financing Charges |
|
-36.00
|
—
|
| Changes In Cash |
|
1,669.00
|
—
|
| Effect Of Exchange Rate Changes |
|
23.00
|
—
|
| Beginning Cash Position |
|
250.00
|
—
|
| End Cash Position |
|
1,942.00
|
—
|
| Free Cash Flow |
|
1,297.00
-8.01%
|
1,410.00
|
| Interest Paid Supplemental Data |
|
944.00
|
—
|
| Income Tax Paid Supplemental Data |
|
62.00
|
—
|
| Common Stock Issuance |
|
7,048.00
|
0.00
|
| Issuance Of Capital Stock |
|
7,048.00
|
0.00
|
| Sale Of Business |
|
6.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-06-12 View
- 42026-06-09 View
- 8-K2026-06-02 View
- 42026-06-01 View
- 42026-06-01 View
- 42026-06-01 View
- 42026-06-01 View
- 42026-05-26 View
- 42026-05-26 View
- 42026-05-26 View
- 10-Q2026-05-06 View
- 8-K2026-05-06 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|